OVERVIEW OF DIAGNOSIS AND MANAGEMENT OF ULCERATIVE COLITIS
Main Article Content
Abstract
Ulcerative colitis (UC) is a chronic disease affecting the large intestine, increasing worldwide. Nearly 1 million individuals in the United States and Europe are affected by this disease and many more globally. Over a decade, since the publication of the last guideline from the American College of Gastroenterology (ACG) on this topic, the management of the disease has grown increasingly complex with the availability of additional therapeutic classes. In addition, algorithms for initiating, optimizing, and monitoring response to existing therapies have undergone considerable evolution. Among them are the latest ACG Guidelines 2019 and the update of the Japanese Society of Gastroenterology (JSGE) 2020 on the diagnosis and treatment of Ulcerative Colitis. Update according to recommendations to help manage UC, reduce the rate of hospitalization, surgery and cancer complications, and improve the quality of life for patients.
Keywords
Ulcerative colitis, ACG 2019, JSGE 2020
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Fumery M, Singh S, Dulai PS and et al (2018), Natural history of adult ulcerative colitis in population-based cohorts: A systematic review, Clin Gastroenterol Hepatol 2018, 16, pp 343-56.
3. Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki (2021), Evidence-based clinical practice guidelines for inflammatory bowel disease 2020, J Gastroenterol, 56, pp. 489-526.
4. Joseph D. Feuerstein, Kim L. Isaacs, Yecheskel Schneider (2020), AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis, Gastroenterology, 158, pp. 1450-1460.
5. Levesque BG, Sandborn WJ, Ruel J and et al (2015), Converging goals of treatment of inflammatory bowel disease from clinical trials and practice, Gastroenterology, 148, pp. 37-51. 6. Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research on Intractable Diseases, ‘‘Research on Intractable Inflammatory Bowel Disorders’’ (Suzuki Group) (2020), Diagnostic Criteria and Treatment Guidelines for Ulcerative Colitis and Crohn’s Disease (revised version), Reiwa 2nd year shared research report, 2, pp. 1-58.
7. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY and et al (2015), Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: Results from a large retrospective study, Am J Gastroenterol, 110, pp. 1014-1021.
8. Mosli MH, Zou G, Garg SK and et al (2015), C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis, Am J Gastroenterol, 110, pp. 802-819.
9. Narula N, Marshall JK, Colombel JF and et al (2016), Systematic review and meta-analysis:
infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids, Am J Gastroenterol, 111, pp. 477-491.
10. Regueiro M, Greer JB, Szigethy E (2017), Etiology and treatment of pain and psychosocial issues in patients with inflammatory bowel diseases, Gastroenterology, 152, pp. 430–439.
11. Shah SC, Ten Hove JR, Castaneda D and et al (2018), High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease, Clin Gastroenterol Hepatol, 16, pp. 1106-1113.
12. Turner D, Levine A, Escher JC and et al (2012), Management of pediatric ulcerative colitis: Joint ECCO and ESPGHAN evidence-based consensus guidelines, J Pediatr Gastroenterol Nutr, 55, pp. 340-361.